Compare · JNJ vs SNSE
JNJ vs SNSE
Side-by-side comparison of Johnson & Johnson (JNJ) and Sensei Biotherapeutics Inc. (SNSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and SNSE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 32773.4x SNSE ($18.6M).
- Over the past year, JNJ is up 53.9% and SNSE is up 73.4% - SNSE leads by 19.5 points.
- JNJ has been more active in the news (7 items in the past 4 weeks vs 1 for SNSE).
- JNJ has more recent analyst coverage (25 ratings vs 10 for SNSE).
- Company
- Johnson & Johnson
- Sensei Biotherapeutics Inc.
- Price
- $253.01+1.39%
- $13.91+7.00%
- Market cap
- $609.12B
- $18.6M
- 1M return
- +7.55%
- -34.01%
- 1Y return
- +53.90%
- +73.44%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 10
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Sensei Biotherapeutics Inc.
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
Latest SNSE
- Chief Financial Officer Stephenson Brian C bought $326,127 worth of shares (13,634 units at $23.92) (SEC Form 4)
- Chief Financial Officer Stephenson Brian C bought $401,269 worth of shares (15,641 units at $25.65) (SEC Form 4)
- Chief Financial Officer Stephenson Brian C bought $405,921 worth of shares (17,413 units at $23.31) (SEC Form 4)
- President and CEO Parikh Anand Kiran bought $55,447 worth of shares (2,806 units at $19.76) and exercised 53,465 shares at a strike of $1.16, increasing direct ownership by 7% to 817,699 units (SEC Form 4)
- SEC Form 3 filed by new insider Stephenson Brian C
- SEC Form SCHEDULE 13G filed by Sensei Biotherapeutics Inc.
- SEC Form 8-K filed by Sensei Biotherapeutics Inc.
- SEC Form S-3ASR filed by Sensei Biotherapeutics Inc.
- SEC Form 4 filed by Director Ramasastry Saira
- President and CEO Parikh Anand Kiran converted options into 761,428 shares (SEC Form 4)